CN104530029A - Heterocyclic compounds as factor Xa inhibitors as well as using methods and application of heterocyclic compounds - Google Patents
Heterocyclic compounds as factor Xa inhibitors as well as using methods and application of heterocyclic compounds Download PDFInfo
- Publication number
- CN104530029A CN104530029A CN201410752242.6A CN201410752242A CN104530029A CN 104530029 A CN104530029 A CN 104530029A CN 201410752242 A CN201410752242 A CN 201410752242A CN 104530029 A CN104530029 A CN 104530029A
- Authority
- CN
- China
- Prior art keywords
- compound
- acid
- present
- heteroaryl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
The invention provides heterocyclic compounds as shown in the formula (I) or stereoisomers, tautomers, nitrogen oxides, solvates, metabolites and pharmaceutically-acceptable salts or prodrugs of the heterocyclic compounds for inhibiting factors Xa. R1 in the formula (I) is heteroaryl which is optionally substituted by halogens; X is -O-, -NH-, -S- or -CH2-; and L is -NHC(=O)-C(=O)NH-, -NHC(=O)- or -C(=O)NH-. The invention also provides pharmaceutical compositions containing the heterocyclic compounds and methods for preventing or treating thromboembolic diseases by using the heterocyclic compounds provided by the invention or the pharmaceutical compositions containing the heterocyclic compounds.
Description
Technical field
The invention belongs to technical field of pharmaceuticals, be specifically related to the heterogeneous ring compound as Xa factor inhibitor and pharmaceutical composition thereof, and described heterogeneous ring compound and pharmaceutical composition thereof the purposes in prevention or treatment thrombotic disease.
Background technology
Thrombotic disease is a kind of common disease, and often show as myocardial infarction, Ischemic Cerebral Infarction, venous thromboembolism etc., its sickness rate, disability rate and mortality ratio are very high.Thrombus disease is caused by thrombosis and embolism.Under certain pathological conditions, blood ingredient forms thrombus at Ink vessel transfusing.Thrombus is come off by forming part, with the some or all of blocking vein of meeting or feeding artery in blood flow process, causes blood vessel or global ischemia, a series of pathologic process such as anoxic and necrosis.Thrombosis and cardiovascular disorder closely related, be threaten one of healthy important diseases of the elderly.
Xa factor is the thrombin that a kind of formation to zymoplasm has vital role, can be zymoplasm by conversion of prothrombin, is an anticoagulation target spot having clinical value.Xa factor is positioned at the joint of inside and outside source property coagulation pathway, and the major catalytic II factor is factor converting to IIa.The bio signal existed due to coagulation process amplifies, and an Xa factor inhibitor can suppress the physiologic effect of 138 thrombogen molecules, thus, can the effectively generation of Trombin inhibiting and the formation of thrombus by suppression Xa factor.Therefore effective and special Xa factor inhibitor is needed to be used as potential valuable therapeutical agent to treat thromboembolic disorders.
The present invention devises a series of new compound, and finds that these compounds exhibit go out excellent effect and effect.Especially the invention provides a kind of stronger to Xa factor restraining effect, active better, the compound that genotoxic potential is less.
Summary of the invention
Heterogeneous ring compound provided by the invention is as Xa factor inhibitor, and it has the selectivity of height to Xa factor, also can suppress the Xa factor of bonding state except the Xa factor that can suppress in unbound state.It is high that the compounds of this invention has bioavailability, and disease therapy spectrum is wide, and dose-effect relationship is stablized, and anticoagulant effect is measurable, without the need to monitoring anticoagulating active, with food and drug interaction little, the features such as Clinical practice is convenient.
The present invention also provides the method for this compounds of preparation and the pharmaceutical composition containing this compounds.
Heterogeneous ring compound provided by the invention and pharmaceutical composition thereof may be used for the medicine preparing treatment thrombotic disease.
On the one hand, the present invention relates to a kind of compound, its steric isomer for compound shown in the compound shown in formula (I) or formula (I), tautomer, oxynitride, solvate, meta-bolites, pharmacy acceptable salt or its prodrug
Wherein:
R
1for heteroaryl, wherein said heteroaryl is optionally optionally substituted by halogen;
X is-O-,-NH-,-S-or-CH
2-; With
L is-NHC (=O)-C (=O) NH-,-NHC (=O)-or-C (=O) NH-.
In one embodiment, R
1for 5-6 former molecular heteroaryl, described 5-6 former molecular heteroaryl is optionally optionally substituted by halogen.
In one embodiment, R
1for pyridyl, pyrimidyl, thienyl, pyrryl or furyl, described pyridyl, pyrimidyl, thienyl, pyrryl and furyl are independent to be optionally optionally substituted by halogen.
In one embodiment, R
1for pyridyl, pyrryl or thienyl, described pyridyl, pyrryl and thienyl are independent optionally to be replaced by chlorine atom.
In one embodiment, X is-O-or-CH
2-.
In one embodiment, compound of the present invention has one of following structure:
or its steric isomer, tautomer, oxynitride, solvate, meta-bolites, pharmacy acceptable salt or its prodrug.
On the other hand, present invention also offers a kind of pharmaceutical composition, comprise compound of the present invention.
In one embodiment, the pharmaceutical composition that the present invention relates to comprises pharmaceutically acceptable carrier, vehicle, thinner, assistant agent, vehicle or their combination further.
On the other hand, present invention also offers a kind of compound of the present invention or pharmaceutical composition of using for the preparation of preventing, processing, alleviate or treat the purposes in the medicine of thrombotic disease.
In one embodiment, thrombotic disease of the present invention is acute coronary syndrome, the first myocardial infarction, recurrent cardiac infarction, stenocardia, the outbreak of of short duration local asphyxia, periphery obstructive arterial disease, venous thrombosis, dvt formation, thrombophlebitis, arterial thrombosis, coronary embolism formed, block and restenosis after revascularization or aortocoronary bypass, cerebral artery thrombosis formation, apoplexy, cerebral embolism, renal infarction or pulmonary infarction again.
On the other hand, the present invention includes all suitable isotropic substance change of different compound.The isotropic substance change of the compounds of this invention is defined as: wherein at least one atom is had same atoms ordinal number but different from the atomic mass that usual occurring in nature finds, and preferably enriches most isotopic atom and replaces.The isotopic example can introducing the compounds of this invention comprises hydrogen, carbon, nitrogen, oxygen, sulphur, and fluorine and chlorine, such as, be respectively: H
2, H
3, C
11, C
13, C
14, N
15, O
17, O
18, S
35, F
18and Cl
36.Some isotropic substance change of the present invention, such as, those wherein introduce radioisotopic compound, such as: introduce H
3or C
14, very useful in the research that medicine and/or matrix organization distribute.Containing tritium, that is: H
3, and carbon-14, that is: C
14isotropic substance because they are easy to preparation and detectability and particularly preferably.In addition, due to larger metabolic stability, by isotropic substance, such as: deuterium, that is: H
2replace the treatment advantage that can provide certain, such as, the transformation period in vivo increased, the dose demand of minimizing, and be therefore preferred in some cases.The isotropic substance change of the compounds of this invention can be prepared by traditional method substantially, uses the suitable isotropic substance change of suitable agent.
On the other hand, structural formula described in the invention comprises all stereoisomeric forms in any ratio (enantiomerisms, diastereo-isomerism, with rotamerism (or conformational isomerism)): R, S configuration such as containing asymmetric center, (Z), (E) isomer of double bond, and (Z), (E) conformer.Therefore, the single three-dimensional chemical isomer of compound of the present invention or its enantiomer, diastereomer, or the mixture of geometrical isomer (or conformer) all belongs to scope of the present invention.
On the other hand, all tautomeric forms of compound of the present invention are included within scope of the present invention.
On the other hand, the oxynitride of the compounds of this invention is also contained within scope of the present invention.Can by using conventional oxygenant (such as hydrogen peroxide) at an elevated temperature, under having the acid of such as acetic acid to exist, be oxidized corresponding nitrogenous alkaline matter, or by be applicable to solvent in cross acid-respons, such as react with peracetic acid in methylene dichloride, ethyl acetate or methyl acetate, or react with 3-chloroperoxybenzoic acid in chloroform or methylene dichloride, prepare the oxynitride of the compounds of this invention.
On the other hand, the salt of the compounds of this invention comprises pharmacy acceptable salt; Also comprise for the preparation of or purifying formula (I) shown in the salt of enantiomer of compound separation shown in the intermediate of compound or formula (I), but not necessarily pharmacy acceptable salt.
If compound of the present invention is alkaline, then conceivable salt can be prepared by any suitable method that document provides, and such as, uses mineral acid, example hydrochloric acid, Hydrogen bromide, sulfuric acid, nitric acid and phosphoric acid etc.Or use organic acid, as acetic acid, toxilic acid, succsinic acid, amygdalic acid, fumaric acid, propanedioic acid, pyruvic acid, oxalic acid, hydroxyethanoic acid and Whitfield's ointment; Pyrans saccharic acid, as glucuronic acid and galacturonic acid; Alpha-hydroxy acid, as citric acid and tartrate; Amino acid, as aspartic acid and L-glutamic acid; Aromatic acid, as phenylformic acid and styracin; Sulfonic acid, as tosic acid, ethyl sulfonic acid, etc.
If compound of the present invention is acid, then conceivable salt can be prepared by suitable method, e.g., uses mineral alkali or organic bases, as ammonia (uncle's ammonia, parahelium, tertiary ammonia), and alkali metal hydroxide or alkaline earth metal hydroxides, etc.Suitable salt comprises, but is not limited to, from the organic salt that amino acid obtains, as glycine and arginine, and ammonia, as uncle ammonia, parahelium and tertiary ammonia, and ring-type ammonia, as piperidines, morpholine and piperazine etc., and from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminium and lithium obtain inorganic salt.
Definition and general terms
All documents that the present invention quotes from, their full content is incorporated to herein by reference, and if the implication expressed by these documents and the present invention inconsistent time, be as the criterion with statement of the present invention.In addition, the various term that the present invention uses and phrase have and well known to a person skilled in the art general sense, nonetheless, the present invention still wishes to be described in more detail at this these terms and phrase and to explain, the term mentioned and phrase, if any inconsistent with common art-recognized meanings, are as the criterion with the implication that the present invention states.The term no matter discussed occurs separately or combination appearance, and definition described herein is all applicable.
According to object of the present invention, chemical element according to the periodic table of elements, CAS version and pharmaceutical chemicals handbook, 75,
thed, 1994 define.In addition, organic chemistry General Principle is shown in " Organic Chemistry; " Sorrell et al., University Science Books, Sausalito:1999, and " March's Advanced Organic Chemistry; " by Smith et al., John Wiley & Sons, New York:2007, therefore all contents have all merged reference.
Except as otherwise noted or in context, have obvious conflict, article used herein " ", " one (kind) " and " described " are intended to comprise " at least one " or " one or more ".Therefore, these articles used herein refer to the article of one or more than one (i.e. at least one) object.Such as, " component " refers to one or more component, more than one component namely may be had to be taken into account in the embodiment of described embodiment and adopt or use.
The present invention says that the term " patient " of use refers to people's (comprising adult and children) or other animals.In some embodiments, " patient " refers to people.
As described in the invention, compound of the present invention can optionally replace by one or more substituting group, as general formula compound above, or special example inside picture embodiment, subclass, and the compounds that the present invention comprises.
Term " optionally " or " optionally " refer to that the event that describes subsequently or situation may instead of necessarily occur, and this description comprises the situation that wherein said event or situation occur, and situation about not occurring.
Term " replacement " or " replacement ", represent one or more hydrogen atoms in described structure replace by concrete substituting group.Unless other aspects show, a group replaced can have a substituting group to replace in each commutable position of group.Not only one or more substituting groups that position can be selected from concrete group in given structural formula replaced, and so substituting group can replace in each position identical or differently.
Term " optionally by .... replaced " or " optionally by .... replace ", can " not replace or quilt ... .. replaced " to exchange with term and use, namely described structure is unsubstituted or is replaced by one or more substituting group of the present invention, substituting group of the present invention comprises, but be not limited to D, F, Cl, N
3,-CN ,-OH ,-SH ,-NH
2, alkyl, alkoxyl group, alkylamino, heterocyclic radical, aryl, heteroaryl, etc.
In addition, it should be noted that, unless otherwise explicitly pointed out, adopted in the present invention describing mode " each ... be separately " and " ... be independently of one another " and " ... be independently " can exchange, all should be interpreted broadly, it both can refer in different group, did not affect mutually between concrete option expressed between same-sign, also can represent in identical group, not affect mutually between concrete option expressed between same-sign.
Term " comprises " for open language, namely comprises the content specified by the present invention, but does not get rid of otherwise content.
At each several part of this specification sheets, the come into the open substituting group of compound of the present invention is open according to radical species or scope.Particularly point out, each the independently sub-combinations thereof that the present invention includes each member of these radical species and scope.Such as, term " C
1-
6alkyl " refer in particular to independent disclosed methyl, ethyl, C
3alkyl, C
4alkyl, C
5alkyl and C
6alkyl.
At each several part of the present invention, describe connection substituting group.When this structure clearly needs linking group, be interpreted as linking group for the Ma Kushi variable cited by this group.Such as, if this structure needs linking group and Ma Kushi group definition for this variable lists " alkyl " or " aryl ", then should be appreciated that, " alkyl " or " aryl " alkylidene group or the arylene group of connection should be represented respectively.
The term " alkyl " that the present invention uses or " alkyl group ", represent containing 1-20 carbon atom, saturated straight or branched univalent hydrocarbyl group, wherein, the substituting group that described alkyl group can optionally be described by one or more the present invention replace.Unless otherwise detailed instructions, alkyl group contains 1-20 carbon atom.In one embodiment, alkyl group contains 1-12 carbon atom; In another embodiment, alkyl group contains 1-6 carbon atom; In yet another embodiment, alkyl group contains 1-4 carbon atom; Also in one embodiment, alkyl group contains 1-3 carbon atom.Described alkyl group optionally replace by one or more substituting group described in the invention.
The example of alkyl group comprises, but is not limited to, methyl (Me ,-CH
3), ethyl (Et ,-CH
2cH
3), n-propyl (n-Pr ,-CH
2cH
2cH
3), sec.-propyl (i-Pr ,-CH (CH
3)
2), normal-butyl (n-Bu ,-CH
2cH
2cH
2cH
3), isobutyl-(i-Bu ,-CH
2cH (CH
3)
2), sec-butyl (s-Bu ,-CH (CH
3) CH
2cH
3), the tertiary butyl (t-Bu ,-C (CH
3)
3), n-pentyl (-CH
2cH
2cH
2cH
2cH
3), 2-amyl group (-CH (CH
3) CH
2cH
2cH
3), 3-amyl group (-CH (CH
2cH
3)
2), 2-methyl-2-butyl (-C (CH
3)
2cH
2cH
3), 3-methyl-2-butyl (-CH (CH
3) CH (CH
3)
2), 3-methyl isophthalic acid-butyl (-CH
2cH
2cH (CH
3)
2), 2-methyl-1-butene base (-CH
2cH (CH
3) CH
2cH
3), n-hexyl (-CH
2cH
2cH
2cH
2cH
2cH
3), 2-hexyl (-CH (CH
3) CH
2cH
2cH
2cH
3), 3-hexyl (-CH (CH
2cH
3) (CH
2cH
2cH
3)), 2-methyl-2-amyl group (-C (CH
3)
2cH
2cH
2cH
3), 3-methyl-2-amyl group (-CH (CH
3) CH (CH
3) CH
2cH
3), 4-methyl-2-amyl group (-CH (CH
3) CH
2cH (CH
3)
2), 3-methyl-3-amyl group (-C (CH
3) (CH
2cH
3)
2), 2-methyl-3-amyl group (-CH (CH
2cH
3) CH (CH
3)
2), 2,3-dimethyl-2-butyl (-C (CH
3)
2cH (CH
3)
2), 3,3-dimethyl-2-butyl (-CH (CH
3) C (CH
3)
3), n-heptyl, n-octyl, etc.
Term " alkoxyl group " represents that alkyl group is connected with molecule rest part by Sauerstoffatom, and wherein alkyl group has implication as described in the present invention.Unless otherwise detailed instructions, described alkoxy base contains 1-12 carbon atom.In one embodiment, alkoxy base contains 1-6 carbon atom; In another embodiment, alkoxy base contains 1-4 carbon atom; In yet another embodiment, alkoxy base contains 1-3 carbon atom.The substituting group that described alkoxy base is optionally described by one or more the present invention replace.
The example of alkoxy base comprises, but is not limited to, methoxyl group (MeO ,-OCH
3), oxyethyl group (EtO ,-OCH
2cH
3), 1-propoxy-(n-PrO, n-propoxy-,-OCH
2cH
2cH
3), 2-propoxy-(i-PrO, i-propoxy-,-OCH (CH
3)
2), 1-butoxy (n-BuO, n-butoxy ,-OCH
2cH
2cH
2cH
3), 2-methyl-l-propoxy-(i-BuO, i-butoxy ,-OCH
2cH (CH
3)
2), 2-butoxy (s-BuO, s-butoxy ,-OCH (CH
3) CH
2cH
3), 2-methyl-2-propoxy-(t-BuO, t-butoxy ,-OC (CH
3)
3), 1-pentyloxy (n-pentyloxy ,-OCH
2cH
2cH
2cH
2cH
3), 2-pentyloxy (-OCH (CH
3) CH
2cH
2cH
3), 3-pentyloxy (-OCH (CH
2cH
3)
2), 2-methyl-2-butoxy (-OC (CH
3)
2cH
2cH
3), 3-methyl-2-butoxy (-OCH (CH
3) CH (CH
3)
2), 3-methyl-l-butoxy (-OCH
2cH
2cH (CH
3)
2), 2-methyl-l-butoxy (-OCH
2cH (CH
3) CH
2cH
3), etc.
Term " halogen " and " halo " refer to fluorine (F), chlorine (Cl), bromine (Br) or iodine (I).
Term " heteroatoms " represents one or more oxygen (O), sulphur (S), nitrogen (N), phosphorus (P) or silicon (Si), comprise nitrogen (N), the form of sulphur (S) and phosphorus (P) any oxidation state; The form of primary, secondary, tertiary amine and quaternary ammonium salt; Or the form that the hydrogen in heterocycle on nitrogen-atoms is substituted, such as, N (N as in 3,4-dihydro-2 h-pyrrole base), NH (NH as in pyrrolidyl) or NR (NR as in the pyrrolidyl that N-replaces).
Term " heteroaryl " represents containing 5-12 annular atoms, or 5-10 annular atoms, or the monocycle of 5-6 annular atoms, dicyclo and three-ring system, wherein at least one member ring systems is aromatic, and at least one member ring systems comprises one or more heteroatoms, wherein each member ring systems comprises 5-7 former molecular ring.Heteroaryl groups is usual, but is necessarily connected with parent molecule by the aromaticity ring of heteroaryl groups.Term " heteroaryl " can with term " hetero-aromatic ring ", " fragrant heterocycle " or " heteroaromatics " exchange use.Described heteroaryl groups optionally replace by one or more substituting group described in the invention.In one embodiment, 5-10 former molecular heteroaryl comprises 1,2,3 or 4 and is independently selected from O, the heteroatoms of S and N.TV structure and determining, heteroaryl can be monoradical or divalent group (that is, inferior heteroaryl).Term " inferior heteroaryl " represents the heteroaryl of divalence.
The example of heteroaryl groups comprises, but be not limited to, 2-furyl, 3-furyl, TMSIM N imidazole base, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, N-pyrryl, 2-pyrryl, 3-pyrryl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-pyrimidyl, pyridazinyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, tetrazyl (as 5-tetrazyl), triazolyl (as 2-triazolyl and 5-triazolyl), 2-thienyl, 3-thienyl, pyrazolyl (as 2-pyrazolyl), isothiazolyl, 1, 2, 3-oxadiazolyl, 1, 2, 5-oxadiazolyl, 1, 2, 4-oxadiazolyl, 1, 2, 3-triazolyl, 1, 2, 3-thio biphosphole base, 1, 3, 4-thio biphosphole base, 1, 2, 5-thio biphosphole base, pyrazinyl, 1, 3, 5-triazinyl, also following dicyclo is comprised, but be never limited to these dicyclos: benzimidazolyl-, benzofuryl, benzothienyl, indyl (as 2-indyl), purine radicals, quinolyl is (as 2-quinolyl, 3-quinolyl, 4-quinolyl), isoquinolyl is (as 1-isoquinolyl, 3-isoquinolyl or 4-isoquinolyl), imidazo [1, 2-a] pyridyl, pyrazolo [1, 5-a] pyridyl, pyrazolo [1, 5-a] pyrimidyl, imidazo [1, 2-b] pyridazinyl, [1, 2, 4] triazolo [4, 3-b] pyridazinyl, [1, 2, 4] triazolo [1, 5-a] pyrimidyl, [1, 2, 4] triazolo [1, 5-a] pyridyl, etc..
Term " n former molecular ", wherein n is integer, typically describes the number of ring member nitrogen atoms in molecule, and in described molecule, the number of ring member nitrogen atoms is n.Such as, piperidyl is 6 former molecular Heterocyclylalkyls, and 1,2,3,4-naphthane is 10 former molecular groups of naphthene base.
Term " steric isomer " refers to have identical chemical constitution, but atom or the group compound that spatially arrangement mode is different.Steric isomer comprises enantiomer, diastereomer, conformer (rotational isomer), geometry (cis/trans) isomer, atropisomer, etc.
Term " diastereomer " refers to two or more chiral centres and the steric isomer of its molecule not mirror image each other.Diastereomer has different physical propertiess, as fusing point, boiling point, spectral quality and reactivity.Non-enantiomer mixture is by high resolution analysis operation as electrophoresis and chromatogram, and such as HPLC is separated.
Term " enantiomer " refer to two of a compound can not be overlapping but be mutually the isomer of mirror.
Term " racemoid " or " racemic mixture " be optically active two the corresponding isomer species of hypodactylia etc. molar mixture.
Term " chirality " is that have can not the molecule of overlapping character with its mirror image; And " achirality " refer to can be overlapping with its mirror image molecule.
Stereochemical definitions Sum fanction used in the present invention generally follows S.P.Parker, Ed., McGraw-Hill Dictionary of ChemicalTerms (1984) McGraw-Hill Book Company, New York; And Eliel, E.and Wilen, S., " Stereochemistry of OrganicCompounds ", John Wiley & Sons, Inc., New York, 1994.
Many organic compound exist with optical active forms, and namely they have the ability that the plane of plane polarized light is rotated.When describing optically active compound, prefix D and L or R and S is used to represent the absolute configuration of molecule about one or more chiral centre.Prefix d and l or (+) and (-) are the symbols being used to specify plane polarized light rotation caused by compound, and wherein (-) or l represent that compound is left-handed.Prefix is the compound of (+) or d is dextrorotation.Concrete steric isomer is an enantiomer, and the mixture of this isomer is called enantiomeric mixture.The 50:50 mixture of enantiomer is called racemic mixture or racemic modification, when not having stereoselectivity or stereospecificity in chemical reaction or process, can occur this situation.
Come into the open any asymmetric atom (such as, carbon etc.) of compound of the present invention can exist with the form of racemize or enantiomorph enrichment, such as (R)-, (S)-or (R, S)-configuration exist.In certain embodiments, each asymmetric atom has at least 50% enantiomeric excess in (R)-or (S)-configuration, at least 60% enantiomeric excess, at least 70% enantiomeric excess, at least 80% enantiomeric excess, at least 90% enantiomeric excess, at least 95% enantiomeric excess, or at least 99% enantiomeric excess.
According to the selection of starting material and method, the compounds of this invention can with in possible isomer or their mixture, and the form of such as racemic modification and non-corresponding isomer mixture (this depends on the quantity of unsymmetrical carbon) exists.Optically active (R)-or (S)-isomer can use chiral synthon or chiral reagent preparation, or use routine techniques to split.If compound contains a double bond, substituting group may be E or Z configuration; If containing dibasic cycloalkyl in compound, the substituting group of cycloalkyl may have cis or transconfiguration.
The mixture of any steric isomer of gained can be separated into pure or substantially pure geometrical isomer according to the difference in component physicochemical property, enantiomer, diastereomer, such as, by chromatography and/or Steppecd crystallization.
By known method, the method that the racemic modification of any gained end product or intermediate is familiar with by those skilled in the art can be split into optical antipode, e.g., by being separated its diastereoisomeric salt obtained.Racemic product also can be separated by chiral chromatography, e.g., uses the high performance liquid chromatography (HPLC) of chiral sorbent.Especially, enantiomer can be prepared by asymmetric synthesis, such as, can with reference to Jacques, et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Principles of Asymmetric Synthesis (2
nded.Robert E.Gawley, Jeffrey Aub é, Elsevier, Oxford, UK, 2012); Eliel, E.L.Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); Wilen, S.H.Tables of Resolving Agentsand Optical Resolutions p.268 (E.L.Eliel, Ed., Univ.of Notre Dame Press, Notre Dame, IN 1972); ChiralSeparation Techniques:A Practical Approach (Subramanian, G.Ed., Wiley-VCH Verlag GmbH & Co.KGaA, Weinheim, Germany, 2007).
Term " tautomer " or " tautomeric form " refer to the constitutional isomer transformed mutually by low energy barrier (low energy barrier) with different-energy.If tautomerism is possible (as in the solution), then can reach the chemical equilibrium of tautomer.Such as, proton tautomer (protontautomer) (also referred to as Prototropic tautomers (prototropic tautomer)) comprises the mutual conversion undertaken by proton shifting, as keto-enol isomerization and imine-enamine isomerizations.Valence tautomerism body (valence tautomer) comprises the mutual conversion undertaken by the restructuring of some bonding electronss.The specific examples of keto-enol tautomerism is the change of pentane-2,4-diketone and 4-hydroxyl penta-3-alkene-2-keto tautomer.Another example tautomeric is phenol-keto tautomerism.A specific examples of phenol-keto tautomerism is the change of pyridine-4-alcohol and pyridine-4 (1H)-one tautomer.Unless otherwise noted, all tautomeric forms of the compounds of this invention all within the scope of the present invention.
" pharmaceutically acceptable " refers to some compounds, raw material, composition and/or formulation like this, they are in the scope that rational medicine judges, to be applicable to patient tissue contacts and without excessive toxicity, pungency, transformation reactions or the other problems symmetrical with rational interests/Hazard ratio and complication, and to be effective to given application.
Unless other aspects show, all tautomeric forms of compound of the present invention are included within scope of the present invention.In addition, unless other aspects show, the structural formula of compound described in the invention comprises the enriched isotope of one or more different atom.
Term used in the present invention " prodrug ", represents a compound and is converted into the compound shown in formula (I) in vivo.Such conversion by prodrug be hydrolyzed in blood or blood or tissue in through enzymatic conversion be the impact of precursor structure.Prodrug compounds of the present invention can be ester, and in existing invention, ester can have phenyl ester class, aliphatics (C as prodrug
1-24) ester class, acyloxymethyl ester class, carbonic ether, amino formate and amino acid esters.Such as, a compound in the present invention comprises OH group, namely its acidylate can be obtained the compound of prodrug form.Other prodrug form comprises phosphoric acid ester, if these phosphate compounds are that di on parent obtains.Can with reference to Publication about Document about the complete discussion of prodrug: Higuchi et al., Pro-drugs as Novel Delivery Systems, Vol.14, A.C.S.Symposium Series; Roche et al., ed., Bioreversible Carriers in Drug Design, American PharmaceuticalAssociation and Pergamon Press, 1987; Rautio et al., Prodrugs:Design and Clinical Applications, Nature ReviewsDrug Discovery, 2008,7,255-270, and Hecker et al, Prodrugs of Phosphates and Phosphonates, J.Med.Chem., 2008,51,2328-2345, every section of document is contained in this by reference.
" meta-bolites " refers to concrete compound or its salt in vivo by product that metabolism obtains.The meta-bolites of a compound can be identified by the known technology in affiliated field, and its activity can be characterized by such method of test that adopts as described in the present invention.Such product can be by passing through oxidation to drug compound, and reduction, hydrolysis, amidated, desamido-effect, esterification, fat abstraction, enzymatic lysis etc. method obtains.Correspondingly, the present invention includes the meta-bolites of compound, comprise and compound of the present invention and Mammals fully contacted the meta-bolites that for some time produces.
Term " pharmacy acceptable salt " refers within the scope of reliable medical judgment, is suitable for not occurring excessive toxicity, stimulation, anaphylaxis etc. with the mankind and zootic contact tissue, and the salt matched with rational effect/Hazard ratio.Pharmacologically acceptable salts is well known in the art.Such as, S.M.Berge, et al., J.Pharmaceutical Sciences, has been described in detail pharmacologically acceptable salts in 1977,66:1.
The salt that pharmaceutically acceptable nontoxic acid is formed comprises, but is not limited to, acetate, adipate, alginates, Citrate trianion, ascorbate salt, aspartate, benzoate, benzene sulfonate, hydrosulfate, borate, butyrates, camphorate, camsilate, cyclopentyl propionate, digluconate, dodecyl sulfate, esilate, formate, gluceptate, glycerophosphate, gluconate, Hemisulphate, enanthate, hexanoate, fumarate, hydrochloride, hydrobromate, hydriodate, 2-hydroxy-ethanesulfonate salt, lactobionate, lactic acid salt, maleate, lauroleate, lauryl sulfate, malate, malonate, mesylate, nicotinate, 2-naphthalenesulfonate, oxalate, nitrate, oleate, palmitate, pamoate, pectate, persulphate, 3-phenylpropionic acid salt, picrate, Pivalate, propionic salt, succinate, tartrate, stearate, thiocyanate-, phosphoric acid salt, glutaminate, supercarbonate, tosilate, undecane hydrochlorate, valerate etc.The salt obtained by suitable alkali comprises basic metal, alkaline-earth metal, ammonium and N
+(C
1-C
4alkyl)
4salt.The quaternary ammonium salt that the compound that the present invention also intends the group contemplating any comprised N is formed.Water-soluble or oil soluble or dispersion product can be obtained by quaternization.Basic metal or alkaline earth salt comprise sodium, lithium, potassium, calcium, magnesium, etc.Pharmacy acceptable salt comprises suitable, nontoxic ammonium further, the amine positively charged ion that quaternary ammonium salt and gegenions are formed, as halogenide, and oxyhydroxide, carboxylate, hydrosulfate, phosphoric acid compound, nitric acid compound, C
1-C
8azochlorosulfonate acid compound and aromatic sulphonic acid compound.
Term " solvate " refers to the associated complex that one or more solvent molecule and compound of the present invention are formed.The solvent forming solvate comprises, but is not limited to, water, Virahol, ethanol, methyl alcohol, methyl-sulphoxide, ethyl acetate, acetic acid, thanomin or its mixture.
When described solvent is water, term " hydrate " can be used.In certain embodiments, a compounds of this invention molecule can combine with a water molecules, such as monohydrate; In other embodiment, a compounds of this invention molecule can combine with more than one water molecules, such as dihydrate, also has in some embodiments, a compounds of this invention molecule can combine with the water molecules being less than, such as semihydrate.It should be noted that hydrate of the present invention remains with the biological effectiveness of the described compound of nonhydrated form.
Time term " blocking group " or " PG " refer to a substituting group and other reacted with functional groups, be commonly used to block or protect special functional.Such as; " amino blocking group " refer to a substituting group be connected with amino group block or protect in compound amino functional; suitable amido protecting group comprises ethanoyl; trifluoroacetyl group; benzoyl, ethoxy carbonyl, tertbutyloxycarbonyl (BOC); carbobenzoxy-(Cbz) (CBZ), the sub-methoxycarbonyl (Fmoc) of 9-fluorenes and benzyl.Similarly, " hydroxy-protective group " refers to that the substituting group of hydroxyl is used for blocking or protecting the functional of hydroxyl, and suitable blocking group comprises trialkylsilkl, ethanoyl, benzoyl and benzyl." carboxy protective group " refers to that the substituting group of carboxyl is used for blocking or protecting the functional of carboxyl, and general carboxyl-protecting group comprises-CH
2cH
2sO
2ph; cyano ethyl; 2-(TMS) ethyl; 2-(TMS) ethoxyl methyl; 2-(p-toluenesulfonyl) ethyl, 2-(p-nitrophenyl alkylsulfonyl) ethyl, 2-(diphenylphosphino) ethyl; nitro-ethyl, etc.Can reference for the general description of blocking group: Greene et al.; Protective Groups in Organic Synthesis; John Wiley & Sons; New York; 1991 and Kocienski et al., Protecting Groups, Thieme; Stuttgart, 2005.
Term " prevents " or " prevention " refers to that the minimizing of the risk obtaining disease or obstacle (that is: makes at least one clinical symptom of disease in main body, stop development, this main body may in the face of or in advance tendency in the face of this disease, but also do not experience or show the symptom of disease).
Term " treatment significant quantity " refers to when delivering medicine to main body and carrying out disease therapy, and the component of compound is enough to the treatment onset of this disease." treatment significant quantity " can along with compound, disease and severity, and the condition having main body to be treated, the age, body weight, sex etc. and changing.
" treatment " of morbid state comprises: (i) preventing disease state, that is, make to be exposed to or susceptible disease state but also do not experience or show the clinical symptom not developing deeply of morbid state of experimenter of symptom of morbid state; (ii) suppress morbid state, that is, stop the development of morbid state or its clinical symptom, or (iii) alleviates morbid state, that is, make morbid state or its clinical symptom temporarily or forever disappear.
The composition of the compounds of this invention, preparation and administration
The invention provides a kind of pharmaceutical composition, comprise compound or its independent steric isomer of formula (I), the racemize of isomer or non-racemic mixture or its pharmacy acceptable salt or solvate.In an embodiment of the invention, described pharmaceutical composition comprises the pharmaceutically acceptable carrier of at least one, assistant agent or vehicle further, and optionally, other treat and/or prevent composition.
Suitable carrier, assistant agent and vehicle agent be for those skilled in the art know and be described in detail in such as Ansel H.C.et al., Ansel ' s Pharmaceutical Dosage Forms and Drug Delivery Systems (2004) Lippincott, Williams & Wilkins, Philadelphia; Gennaro A.R.et al., Remington:The Science and Practice of Pharmacy (2000) Lippincott, Williams & Wilkins, Philadelphia; With Rowe R.C., Handbook of Pharmaceutical Excipients (2005) Pharmaceutical Press, in Chicago.
Compound of the present invention or composition can by any suitable method administrations, comprise oral (comprise containing clothes and sublingual), locally, rectum, vagina, transdermal, parenteral (intramuscular, intravenously, intra-arterial, intraperitoneal or subcutaneous), in lung, intracutaneous, in sheath and in epidural and nose, and if need for topical therapeutic, intralesional administration.Preferred mode is oral administration, to Intraperitoneal medication or intravenous injection.
For Orally administered, described pharmaceutical composition can adopt such as following form: the tablet prepared by the pharmaceutically acceptable vehicle of ordinary method or capsule, and described vehicle is tackiness agent (such as pregelatinized corn starch, Polyvinylpyrolidone (PVP) or Vltra tears) such as; Weighting agent (such as lactose, Microcrystalline Cellulose or calcium phosphate); Lubricant (such as Magnesium Stearate, talcum or silicon-dioxide); Disintegrating agent (such as yam starch or sodium starch glycolate); Or wetting agent (such as Sodium Lauryl Sulphate BP/USP).Tablet can dressing by means commonly known in the art.
Orally administered liquid preparation can adopt such as following form: solution, syrup or suspension, or can the form of desciccate exist, with the carrier reconstruct be applicable to water or other before use.These liquid preparations can adopt pharmaceutically acceptable additive to prepare by ordinary method, and described additive is suspension agent (edible fat of such as sorbitol syrup, methylcellulose gum or hydrogenation) such as; Emulsifying agent (such as Yelkin TTS and Sudan Gum-arabic); Nonaqueous carrier (such as Prunus amygdalus oil, oily ester or ethanol) and sanitas (as methyl p-hydroxybenzoate or propylparaben or Sorbic Acid).
For sucking and using, described composition can adopt the form of tablet or the lozenge prepared in conventional manner.
The composition being suitable for parental injection can comprise physiologically acceptable sterile, aqueous or non-aqueous liquor, dispersion agent, suspensoid or emulsion, and for reconstructing the sterile powders of sterile injectable solution agent or dispersion agent.Suitable moisture or nonaqueous carrier, thinner, solvent or vectorial example comprise water, ethanol, polyvalent alcohol (propylene glycol, polyoxyethylene glycol, glycerine etc.), vegetables oil (as sweet oil), injectable organic ester as ethyl oleate and their suitable mixture.
These compositions also can contain auxiliary material, as sanitas, wetting agent, emulsifying agent and dispersion agent.By various antibacterial agent and anti-mycotic agent, such as parabens, trichloro-butyl alcohol, phenol, Sorbic Acid etc., can guarantee the effect preventing microorganism.Also expect to comprise isotonic agent, such as carbohydrate, sodium-chlor etc.Such as, by using the material that can postpone to absorb, aluminum monostearate and gelatin, the prolongation that can reach injectable drug form absorbs.
Also suspension agent can be contained in addition to the active compound, the mixture etc. of such as ethoxylation i-octadecanol, polyoxyethylene sorbitol and polyoxyethylene sorbitan esters, Microcrystalline Cellulose, partially aluminium hydroxide, wilkinite, agar and tragacanth gum or these materials in suspensoid.
In some cases, be the effect of prolong drug, expect absorption that is subcutaneous or intramuscular injection of drugs of slowing down.This realizes by using the crystal of poorly water-soluble or the liquid suspension of amorphous substance.Like this, the absorption rate of medicine depends on its dissolution rate, and dissolution rate can be depending on crystallographic dimension and crystal formation.Or, the delay of the medicament forms of parenteral admin absorb by by this medicine dissolution in or be suspended in oily vehicle and realize.
Injectable depot formulations form is by preparing at the microcapsule matrix of biodegradable polymer as formed medicine in polylactide-polyglycolide (polylactide-polyglycolide).According to the character of the ratio of medicine and polymkeric substance and the concrete polymkeric substance adopted, drug releasing rate can be controlled.The example of other biological degradable polymer comprises poe class (poly (orthoesters)) and polyanhydrides (poly (anhydrides)).Injectable depot formulations also can be prepared in the liposome compatible with bodily tissue or micro emulsion by pharmaceutical pack being embedded in.
Injectable formulation can such as by filtering with bacterial filter or carrying out sterilizing by the disinfectant mixing aseptic solid composite form, and described solids composition can be dissolved or dispersed in sterilized water or other sterile injectable medium before use.
The compounds of this invention can be prepared as paste, creme or lotion or be used for epidermis topical as pasting through skin.Paste and creme such as use or oil binder (base) can add suitable thickening material and/or jelling agent preparation.Lotion can use or oil binder preparation, and usually also will containing one or more emulsifying agents, stablizer, dispersion agent, suspension agent, thickening material or tinting material.Be suitable for the formulation of topical in mouth to comprise: lozenge, it is included in flavouring base, the promoting agent in usually sucrose and Acacia or tragacanth gum; Pastille, it is included in the activeconstituents in inertia base-material such as gelatin and glycerine or sucrose and Acacia; And collutory, it is included in the activeconstituents in suitable liquid vehicle.In addition, the pharmaceutical preparation of ophthalmology, ear drop and eye drops are all the scopes that the present invention considers.
The pharmaceutically acceptable composition of the present invention can with the form rectum of suppository or vagina administration.These can form by reagent and suitable non-perfusing adjuvant being mixed with, and this adjuvant is at room temperature solid but is then liquid at the temperature of rectum or vagina, thus melts in rectum or vagina and discharge medicine.Such material comprises cocoa butter, beeswax, and polyethylene glycols.
For using for intranasal administration or by suction, active compound of the present invention is sent easily with the form of the aerosol spray in pressurizing vessel or atomizer or in the capsule of employing sucker or insufflator.In the case of a pressurized aerosol, suitable propellent (such as Refrigerant 12, trichlorofluoromethane, dichloro tetrafluoro ethane, carbonic acid gas or other gas be applicable to) and unitary dose can be determined by the amount providing valve to send through metering.The medicine of pressurizing vessel or atomizer can comprise solution or the suspension of active compound, concerning then its preferred powder type capsule.The capsule and cartridge case (being made up of such as gelatin) that are used for sucker or insufflator can be mixed with the powdered mixture comprising the compounds of this invention and suitable powdered substrate (such as lactose or starch).
" often spraying (puff) " that aerosol formulation for treating above-mentioned illness in average adult is preferably prepared as each dosing or aerosol comprises the compounds of this invention of 20 μ g to 1000 μ g.Every TDD of aerosol is in the scope of 100 μ g to 10mg.Can use several times in one day, such as 2,3,4 or 8 times, give such as 1,2 or 3 dosage at every turn.
Pharmaceutical preparation is preferably unit dosage.In this form, preparation is subdivided into the unitary dose containing appropriate active ingredient.Unit dosage can be the preparation of packaging, and this packaging contains the preparation of discrete magnitude, as tablet, capsule and the powder in bottle or ampoule packed.In addition, unit dosage can be capsule, tablet, cachet or lozenge itself, or can be the packaged form of these formulations any of proper amt.
It should be understood that total daily dosage portion of the compounds of this invention and composition must be maked decision within the scope of reliable medical judgment by attending physician.For any concrete patient, concrete treatment effective dose level must be determined according to many factors, and described factor comprises treated obstacle and the severity of this obstacle; The activity of the particular compound adopted; The concrete composition adopted; Age of patient, body weight, general health situation, sex and diet; The administration time of the particular compound adopted, route of administration and excretion rate; The treatment time length; The medicine combinationally using with adopted particular compound or use simultaneously; And the known similar factor of medical field.Such as, the way of this area is, the dosage of compound, from lower than for obtaining level that required result for the treatment of requires, increases dosage, gradually until obtain required effect.In general, the dosage that formula (I) compound is used for Mammals particularly people can be 0.1-1000mg/kg/day, be preferably 1-100mg/kg/day, taking can be once a day or for several times, and takes medicine for each time and can comprise 1,2 or 3 dosage.
The purposes of the compounds of this invention and composition
The invention provides a kind of novel cpd, described compound can be used as neuraminidase inhibitor.Compound of the present invention is applicable to the medicine making multiple formulation, can be widely used in treatment seasonal influenza, bird flu, porcine influenza and Tamiflu be had to the influenza virus mutant strain of resistance.Compound provided by the invention and pharmaceutical composition can be used for the medicine for the preparation of preventing, processing, alleviate or treat thrombotic disease.The present invention also provides above-claimed cpd or its pharmaceutical composition preparing the purposes in Xa factor inhibitor medicaments.
The present invention also provides a kind of method for preventing, processing, alleviate or treat thrombotic disease, and described method comprises above-claimed cpd or its pharmaceutical composition of the bacterium having treatment needs.Wherein said thrombotic disease is acute coronary syndrome, the first myocardial infarction, recurrent cardiac infarction, stenocardia, the outbreak of of short duration local asphyxia, periphery obstructive arterial disease, venous thrombosis, dvt formation, thrombophlebitis, arterial thrombosis, coronary embolism are formed, block and restenosis after revascularization or aortocoronary bypass, cerebral artery thrombosis formation, apoplexy, cerebral embolism, renal infarction or pulmonary infarction again.Further, above-claimed cpd provided by the invention or its pharmaceutical composition can be used jointly with other therapies or therapeutical agent.Method of application can for simultaneously, order or carry out with certain hour interval.
Implement treatment, prevent or the dosage of the compound that to delay etc. needed for effect or pharmaceutical composition usually depend on use particular compound, patient, disease specific or illness and severity, route of administration and frequency etc., and need to be judged as the case may be by attending doctor.Such as, when by using compound provided by the invention or pharmaceutical composition through intravenous route, can even use with longer time interval once in a week.
Compound of the present invention and pharmaceutical composition, except useful to human treatment, also can be applicable to the Mammals in veterinary treatment pet, the animal of introduced variety and the animal on farm.The example of other animal comprises horse, dog and cat.At this, compound of the present invention comprises its pharmaceutically acceptable derivates.
The synthetic method of compound
For describing the present invention, below list embodiment.But need be appreciated that and the invention is not restricted to these embodiments, only be to provide and put into practice method of the present invention.
Usually, compound of the present invention can be prepared by method described in the invention, and unless there are further instruction, wherein substituent definition is such as formula shown in (I).Reaction scheme below and embodiment are used for illustrating content of the present invention further.
The professional in affiliated field will recognize: chemical reaction described in the invention can be used for preparing many other compounds of the present invention suitably, and is all contemplated within the scope of the present invention for the preparation of other method of compound of the present invention.Such as; synthesis according to the compound of those non-illustrations of the present invention can successfully be completed by modifying method by those skilled in the art; as suitable protection interference group, by the reagent that utilizes other known except described in the invention, or reaction conditions is made the amendment of some routines.In addition, reaction disclosed in this invention or known reaction conditions are also applicable to the preparation of other compounds of the present invention admittedly.
The embodiments described below, to be decided to be degree Celsius unless other aspects show all temperature.Reagent is bought in goods providers as AldrichChemical Company, Arco Chemical Company and Alfa Chemical Company, unless other aspects show, all not through being further purified during use.General reagent is from Xi Long chemical plant, Shantou, Guangdong brilliance chemical reagent factory, Guangzhou Chemical Reagent Factory, Tianjin Hao Yuyu Chemical Company, Tianjin good fortune chemical reagent factory in morning, Wuhan Xin Huayuan development in science and technology company limited, Qingdao Teng Long chemical reagent company limited and Haiyang Chemical Plant, Qingdao buy and obtain.
Anhydrous tetrahydro furan, dioxane, toluene, ether is through sodium Metal 99.5 backflow drying and obtains.Anhydrous methylene chloride and chloroform are through hydrolith backflow drying and obtain.Ethyl acetate, sherwood oil, normal hexane, N,N-dimethylacetamide and DMF are through the prior Dryly use of anhydrous sodium sulphate.
Below reacting is generally under nitrogen or argon gas positive pressure or on anhydrous solvent, overlap a drying tube (unless showing in other), the soft rubber ball that reaction flask is suitable all beyond the Great Wall, and substrate is squeezed into by syringe.Glassware is all dried.
Chromatographic column uses silicagel column.Silica gel (300-400 order) is purchased from Haiyang Chemical Plant, Qingdao.NMR (Nuclear Magnetic Resonance) spectrum is with CDC1
3, d
6-DMSO, CD
3oD or d
6-acetone is solvent (reporting in units of ppm), with TMS (0ppm) or chloroform (7.25ppm) as reference standard.In time there is multiplet, abbreviation below will be used: s (singlet, unimodal), d (doublet, bimodal), t (triplet, triplet), m (multiplet, multiplet), br (broadened, broad peak), dd (doublet of doublets, quartet), dt (doublet of triplets, two triplet).Coupling constant, represents with hertz (Hz).
The condition of Algorithm (MS) data is: (3.5 microns, 6min, flow velocity is 0.6mL/min to Agilent 1200 or Agilent 6120 Series LCMS for pillar model: ZorbaxSB-C18,2.1 × 30mm.Moving phase: 5-95% is (containing the CH of 0.1% formic acid
3cN) (containing the H of 0.1% formic acid
2o) ratio in, detects at 210/254nm UV, by low-response EFI pattern (ESI).
The characteristic manner of pure compound is: Agilent 1100Series high speed liquid chromatography (HPLC), detects at 210nm and 254nm UV.Pillar operates usually at 40 DEG C.
The use of brief word below runs through the present invention:
Aq. the aqueous solution
Ascorbic acid xitix
CH
2cl
2, DCM methylene dichloride
CDC1
3deuterochloroform
DIEA, DIPEA diisopropyl ethyl amine
DMF DMF
DMAP DMAP
DMSO dimethyl sulfoxide (DMSO)
EtOAc, EA ethyl acetate
Et
3n, TEA triethylamine
EDTA ethylenediamine tetraacetic acid (EDTA)
EGTA ethylene glycol diethyl ether ethylenediamine tetraacetic acid (EDTA)
G gram
Glucose glucose
H hour
H
2sO
4sulfuric acid
HBTU benzotriazole-N, N, N', N'-tetramethyl-urea hexafluorophosphate
K
2cO
3salt of wormwood
KI potassiumiodide
KCl Repone K
MeOH, CH
3oH methyl alcohol
MgSO
4magnesium sulfate
ML, ml milliliter
Min minute
M mol/L (mol/L)
N
2nitrogen
RT, rt, r.t. room temperature
NaBH
4sodium borohydride
NH
4c1 ammonia chloride
NaHCO
3sodium bicarbonate
NaCl sodium-chlor
Na
2sO
4sodium sulfate
PE sherwood oil (60-90 DEG C)
THF tetrahydrofuran (THF)
Following synthetic schemes describes preparation the present invention and to come into the open the step of compound.Unless otherwise indicated, R
1with X, there is definition as described in the present invention.
Synthetic schemes 1
The method that target compound 9 can be described by synthetic schemes 1 prepares.Raw material 1 is sloughed a part iodine and is generated aryl lithium compounds 2 under the effect of n-Butyl Lithium; Compound 2 and raw material 3 carry out nucleophilic reaction and generate compound 4; Compound 4 and raw material 5, under cuprous iodide, part (as N, N'-dimethyl-ethylenediamine) and alkali (as salt of wormwood) exist, carry out linked reaction through high temperature in a solvent, obtain compound 6; Compound 6 generates compound 7 with acetonitrile reaction under the effect of acid (as the vitriol oil); Compound 7 is sloughed acetyl protection base and is obtained compound 8; Compound 8 and raw material 10 carry out condensation reaction and obtain target compound 9.
Synthetic schemes 2
The method that target compound 11 can be described by synthetic schemes 2 prepares.Compound 8 and raw material 12 carry out condensation reaction and obtain target compound 11.
Below in conjunction with embodiment, compound provided by the invention, pharmaceutical composition and application thereof are further described.
Embodiment
The chloro-N-of embodiment 1 5-(3-(4-(3-oxomorpholin) phenyl) oxa-ring fourth-3-base) niacinamide
Step 1:(4-iodophenyl) lithium
At nitrogen atmosphere and-78 DEG C, hexane solution (the 34.4mL of the n-Butyl Lithium of 1.6M is slowly dripped in anhydrous tetrahydro furan (100mL) solution of Isosorbide-5-Nitrae-diiodo-benzene (16.5g, 50.0mmol), 55.0mmol), stir 10 minutes at-78 DEG C.Reaction solution is untreated is directly used in next step.
Step 2:3-(4-iodophenyl) oxa-ring fourth-3-alcohol
In (4-iodophenyl) lithium solution of previous step, slowly drip anhydrous tetrahydro furan (40mL) solution of oxa-ring fourth-3-ketone (3.6g, 50.0mmol), continue to stir 10 minutes at-78 DEG C, rise to room temperature.Add water (200mL), aqueous phase ethyl acetate (100mL × 3) extracts.Merge organic phase, with anhydrous sodium sulfate drying, filter, pressure reducing and steaming solvent.Thick product, through column chromatography purification (petrol ether/ethyl acetate (v/v)=6/1), obtains white solid (8.0g, 58%).
Step 3:4-(4-(3-hydroxyl oxygen heterocycle fourth-3-base) phenyl) morpholine-3-ketone
3-(4-iodophenyl) oxa-ring fourth-3-alcohol (4g, 14.5mmol), morpholine-3-ketone (1.76g, 17.4mmol), N, N is added successively in round-bottomed flask
'-dimethyl-ethylenediamine (210mg, 2.38mmol), salt of wormwood (3.3g, 23.88mmol), cuprous iodide (456mg, 2.39mmol) and Isosorbide-5-Nitrae-dioxane (15mL).Under nitrogen protection, be heated to 110 DEG C of stirrings spend the night.Be chilled to room temperature, filter, filtrate decompression boils off solvent, and thick product, through column chromatography purification (ethyl acetate), obtains white solid (2.0g, 55%).
MS(ESI,pos.ion)m/z:250.2[M+H]
+。
Step 4:N-(3-(4-(3-oxomorpholin) phenyl) oxa-ring fourth-3-base) ethanamide
At-15 DEG C, in acetonitrile (5mL) solution of 4-(4-(3-hydroxyl oxygen heterocycle fourth-3-base) phenyl) morpholine-3-ketone (50mg, 0.201mmol), drip the vitriol oil (2mL).Stir 3 hours at-15 DEG C.Pressure reducing and steaming solvent, thick product, through column chromatography purification (ethyl acetate/methanol (v/v)=15/1), obtains quantitative colorless oil.
Step 5:4-(4-(3-amino-3-base) phenyl) morpholine-3-ketone
The aqueous hydrochloric acid (5mL) of 1M is added in N-(3-(4-(3-oxomorpholin) phenyl) oxa-ring fourth-3-base) ethanamide (50mg, 0.172mmol).Be heated to 65 DEG C stir 3 hours.Pressure reducing and steaming solvent, thick product, through column chromatography purification (ethyl acetate/methanol (v/v)=10/1), obtains colorless oil (16mg, 37%).
MS(ESI,pos.ion)m/z:249.2[M+H]
+。
The chloro-N-of step 6:5-(3-(4-(3-oxomorpholin) phenyl) oxa-ring fourth-3-base) niacinamide
To 5-chloropyridine formic acid (8.4mg, N 0.0533mmol), triethylamine (20 μ L are added in dinethylformamide (0.8mL) solution, 0.15mmol) with HBTU (24.3mg, 0.064mmol), stir 10 minutes, then add 4-(4-(3-amino-3-base) phenyl) morpholine-3-ketone (16mg, 0.0644mmol), stirring at room temperature 4 hours.Thick product, through column chromatography purification (methylene chloride/methanol (v/v)=10/1), obtains pale yellow oil (12mg, 77%).
MS(ESI,pos.ion)m/z:406.1[M+H+H
2O]
+；
1H NMR(400MHz,CDCl
3)δ3.61-3.68(m,2H),3.76(t,3H),3.7-3.9(d,2H),4.0(t,2H),4.37(s,2H),7.33(d,2H),7.565(d,2H),7.82(dd,1H),8.13(d,1H),7.85(s,1H),8.30(t,1H),8.48(d,1H)。
The chloro-N-of embodiment 2 5-(3-(4-(3-oxo-morpholine) phenyl) oxa-ring fourth-3-base) thiophene-2-carboxamide derivatives
The chloro-N-of step 1:5-(3-(4-(3-oxo-morpholine) phenyl) oxa-ring fourth-3-base) thiophene-2-carboxamide derivatives
To 5-chlorothiophene-2-formic acid (15mg, N 0.0923mmol), triethylamine (50 μ L are added in dinethylformamide (0.8mL) solution, 0.36mmol) with HBTU (48.6mg, 0.128mmol), stir 10 minutes, then add 4-(4-(3-amino-3-base) phenyl) morpholine-3-ketone (31mg, 0.128mmol), stirring at room temperature 4 hours.Thick product, through column chromatography purification (methylene chloride/methanol (v/v)=10/1), obtains pale yellow oil (20mg, 55%).
MS(ESI,pos.ion)m/z:411.1[M+H+H
2O]
+；
1H NMR(400MHz,CDCl
3)δ3.61-3.68(m,2H),3.72-3.76(m,4H),4.05(t,2H),4.32(s,2H),6.87(d,1H),7.06(t,2H),7.27(d,2H),7.32(d,1H),7.55(d,2H)。
Embodiment 3 N
1-(5-chloropyridine-2-base)-N
2-(3-(4-(3-oxo-morpholine) phenyl) oxa-ring fourth-3-base) oxamide
Step 1:N
1-(5-chloropyridine-2-base)-N
2-(3-(4-(3-oxo-morpholine) phenyl) oxa-ring fourth-3-base) oxamide
To 2-((5-chloropyridine-2-base) is amino)-2-Oxoacetic Acid (48mg, N 0.239mmol), triethylamine (100 μ L are added in dinethylformamide (1mL) solution, 0.72mmol) with HBTU (114mg, 0.3mmol), stir 10 minutes, then add 4-(4-(3-amino-3-base) phenyl) morpholine-3-ketone (160mg, 0.644mmol), stirring at room temperature 4 hours.Thick product, through column chromatography purification (methylene chloride/methanol (v/v)=10/1), obtains pale yellow oil (6.2mg, 6%).
MS(ESI,pos.ion)m/z:449.1[M+H+H
2O]
+；
1H NMR(400MHz,CDCl
3)δ3.65-3.68(m,2H),3.76-3.78(m,4H),4.04(t,2H),4.34(s,2H),7.34(d,2H),7.54(d,2H),7.72(dd,1H),7.87(t,1H),7.85(s,1H),8.16(d,1H),8.31(d,1H),9.71(s,1H)。
Biological activity test
A. mankind FXa enzyme level experiment
The enzymic activity of mankind's factor Xa (FXa) is by the transformation assay for the specific chromogenic substrate of FXa.To this, p-Nitraniline is fallen in factor Xa cracking from chromogenic substrate.This is determined as follows to state and carries out on microwell plate.
Tester is dissolved in the methyl-sulphoxide of 10% by different concns, (10nM is dissolved in 50mM Tris to get compound 5 μ L and mankind FXa, 150mM NaCl, pH=8.3) 10 μ L mix, 15min is hatched in 25 DEG C of constant incubators, FXa chromophoric substrate (800 μMs, sigma) 5 μ L is added, in 25 DEG C of 405nm place kinetic test absorbances after hatching.By the test mixing thing containing test substances and not containing test substances control mixture relatively and calculate IC by these data
50value, test result is as shown in table 1.
B. anticoagulation effect in vitro test
The clotting time of compounds extend rabbit plasma
1. the preparation of each concentration compound
Get each compound working fluid (100mM) of 4 μ L, be diluted to the working fluid of each concentration with methyl-sulphoxide liquid.
2. the preparation of plasma sample
Get some rabbits, auricular vein injects 3% pentobarbital solution (30mg/kg) anesthesia, with the vacuum test tube aorta abdominalis blood sampling containing 3.8% Sodium Citrate 0.2mL to 2mL, collect multitube, turn upside down mixing for several times, leave standstill 10min, in the centrifugal 10min of 3000rpm, draw each pipe blood plasma, all blood plasma is mixed to same centrifuge tube, 1.6mL often pipe packing, it is for subsequent use to insert rapidly-80 DEG C of Refrigerator stores.
3. application of sample and mensuration clotting time PT and APTT
Get out 1.5mL EP manage, often pipe adds 180 μ L plasma specimens; In each pipe blood specimen, add the medicine of 4 μ L respective concentration respectively, control group adds 4 μ L dimethyl sulfoxide solutions, and concussion mixing, hatches 5min for 37 DEG C; PT and APTT is measured with Sysmex CA1500 Automatic coagulometer; Draw amount effect curve, matching is carried out to curve, calculate the concentration (CT of the test compounds that the clotting time of sening as an envoy to doubles thus
2), test result is as shown in table 1.
Table 1 compound is to the restraining effect of people FXa activity and anticoagulation effect in vitro
Conclusion: the compounds of this invention has good factor Xa inhibit activities, has the effect extending the clotting time simultaneously.
C. the solubleness test of compound
In 15mL tapered tube, add water (10mL), vibration limit, limit adds sample, until sample stops dissolving, and 37 DEG C of water bath with thermostatic control jolting 24h, jolting speed 40rpm.After jolting terminates, sample is filtered through water system millipore filtration (0.45 μm, Φ 13mm), discard just filtrate, precision pipettes subsequent filtrate (500 μ L), adds diluent acetonitrile-water (500 μ L, v/v=60/40), the two mixing, obtains need testing solution.
Get need testing solution (40 μ L), adopt HPLC to detect, by one point external standard method calculation sample concentration, result is as shown in table 2.
The solubleness of table 2 the compounds of this invention
| Numbering | Compound solubility (mg/mL) |
| Embodiment 1 | 0.25 |
| Embodiment 2 | 0.21 |
| Embodiment 3 | 0.28 |
Conclusion: the compounds of this invention has good solubleness.
In the description of this specification sheets, specific features, structure, material or feature that the description of reference term " embodiment ", " some embodiments ", " example ", " concrete example " or " some examples " etc. means to describe in conjunction with this embodiment or example are contained at least one embodiment of the present invention or example.In this manual, to the schematic representation of above-mentioned term not must for be identical embodiment or example.And the specific features of description, structure, material or feature can combine in one or more embodiment in office or example in an appropriate manner.In addition, when not conflicting, the feature of the different embodiment described in this specification sheets or example and different embodiment or example can carry out combining and combining by those skilled in the art.
Although illustrate and describe embodiments of the invention above, be understandable that, above-described embodiment is exemplary, can not be interpreted as limitation of the present invention, and those of ordinary skill in the art can change above-described embodiment within the scope of the invention, revises, replace and modification.
Claims (10)
1. a compound, its steric isomer for compound shown in the compound shown in formula (I) or formula (I), tautomer, oxynitride, solvate, meta-bolites, pharmacy acceptable salt or its prodrug,
Wherein:
R
1for heteroaryl, wherein said heteroaryl is optionally optionally substituted by halogen;
X is-O-,-NH-,-S-or-CH
2-; With
L is-NHC (=O)-C (=O) NH-,-NHC (=O)-or-C (=O) NH-.
2. compound according to claim 1, wherein R
1for 5-6 former molecular heteroaryl, described 5-6 former molecular heteroaryl is optionally optionally substituted by halogen.
3. compound according to claim 1, wherein R
1for pyridyl, pyrimidyl, thienyl, pyrryl or furyl, described pyridyl, pyrimidyl, thienyl, pyrryl and furyl are independent to be optionally optionally substituted by halogen.
4. compound according to claim 3, wherein R
1for pyridyl, pyrryl or thienyl, described pyridyl, pyrryl and thienyl are independent optionally to be replaced by chlorine atom.
5. compound according to claim 1, wherein X is-O-or-CH
2-.
6. the compound according to claim 1-5 any one, wherein said compound has one of following structure:
or its steric isomer, tautomer, oxynitride, solvate, meta-bolites, pharmacy acceptable salt or its prodrug.
7. a pharmaceutical composition, comprises the compound described in claim 1-6 any one.
8. pharmaceutical composition according to claim 7, comprises at least one pharmaceutically acceptable carrier, vehicle, thinner, assistant agent or vehicle further.
9. one kind uses the compound described in claim 1-6 any one or the pharmaceutical composition described in claim 7-8 any one for the preparation of preventing, processing, alleviate or treat the purposes in the medicine of thrombotic disease.
10. purposes according to claim 9, wherein said thrombotic disease is acute coronary syndrome, the first myocardial infarction, recurrent cardiac infarction, stenocardia, the outbreak of of short duration local asphyxia, periphery obstructive arterial disease, venous thrombosis, dvt formation, thrombophlebitis, arterial thrombosis, coronary embolism are formed, block and restenosis after revascularization or aortocoronary bypass, cerebral artery thrombosis formation, apoplexy, cerebral embolism, renal infarction or pulmonary infarction again.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410752242.6A CN104530029B (en) | 2014-12-09 | 2014-12-09 | Heterocyclic compounds as factor Xa inhibitors as well as using methods and application of heterocyclic compounds |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410752242.6A CN104530029B (en) | 2014-12-09 | 2014-12-09 | Heterocyclic compounds as factor Xa inhibitors as well as using methods and application of heterocyclic compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104530029A true CN104530029A (en) | 2015-04-22 |
| CN104530029B CN104530029B (en) | 2017-04-12 |
Family
ID=52845700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410752242.6A Active CN104530029B (en) | 2014-12-09 | 2014-12-09 | Heterocyclic compounds as factor Xa inhibitors as well as using methods and application of heterocyclic compounds |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104530029B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3709986A4 (en) * | 2017-11-14 | 2021-05-26 | Merck Sharp & Dohme Corp. | Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
| EP3694506A4 (en) * | 2017-10-09 | 2021-06-09 | Merck Sharp & Dohme Corp. | Novel substituted phenyloxetane and phenyltetrahydrofuran compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1391575A (en) * | 1998-12-23 | 2003-01-15 | 杜邦药品公司 | Nitrogen containing heterobicycles as factor XA inhibitors |
| CN1434822A (en) * | 1999-12-24 | 2003-08-06 | 拜尔公司 | Substituted oxazolidinones and their use in the field of blood coagulation |
| WO2004082687A1 (en) * | 2003-03-18 | 2004-09-30 | Bristol-Myers Squibb Company | Lactam-containing cyclic diamines and derivatives as factor xa inhibitors |
| US20060142263A1 (en) * | 2004-12-24 | 2006-06-29 | Boehringer Ingelheim International Gmbh | New substituted pyrrolidinones, their manufacture and their use as medicaments |
| CN101014591A (en) * | 2004-05-13 | 2007-08-08 | 贝林格尔·英格海姆国际有限公司 | Novel substituted thiophenecarboxamides, their production and their use as medicaments |
| CN101573346A (en) * | 2006-12-31 | 2009-11-04 | 贝林格尔.英格海姆国际有限公司 | Process for the synthesis of derivatives of 3-amino-tetrahydrofuran-3-carboxylic acid and use thereof as medicaments |
-
2014
- 2014-12-09 CN CN201410752242.6A patent/CN104530029B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1391575A (en) * | 1998-12-23 | 2003-01-15 | 杜邦药品公司 | Nitrogen containing heterobicycles as factor XA inhibitors |
| CN1434822A (en) * | 1999-12-24 | 2003-08-06 | 拜尔公司 | Substituted oxazolidinones and their use in the field of blood coagulation |
| WO2004082687A1 (en) * | 2003-03-18 | 2004-09-30 | Bristol-Myers Squibb Company | Lactam-containing cyclic diamines and derivatives as factor xa inhibitors |
| CN101014591A (en) * | 2004-05-13 | 2007-08-08 | 贝林格尔·英格海姆国际有限公司 | Novel substituted thiophenecarboxamides, their production and their use as medicaments |
| US20060142263A1 (en) * | 2004-12-24 | 2006-06-29 | Boehringer Ingelheim International Gmbh | New substituted pyrrolidinones, their manufacture and their use as medicaments |
| CN101573346A (en) * | 2006-12-31 | 2009-11-04 | 贝林格尔.英格海姆国际有限公司 | Process for the synthesis of derivatives of 3-amino-tetrahydrofuran-3-carboxylic acid and use thereof as medicaments |
Non-Patent Citations (1)
| Title |
|---|
| MEGANATHAN CHANDRASEKARAN • SUGUNADEVI SAKKIAH • KEUN WOO LEE: ""Combined chemical feature-based assessment and Bayesian model studies to identify potential inhibitors for Factor Xa"", 《MED. CHEM. RES.》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3694506A4 (en) * | 2017-10-09 | 2021-06-09 | Merck Sharp & Dohme Corp. | Novel substituted phenyloxetane and phenyltetrahydrofuran compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
| US11319295B2 (en) | 2017-10-09 | 2022-05-03 | Merck Sharp & Dohme Corp. | Substituted phenyloxetane and phenyltetrahydrofuran compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
| EP3709986A4 (en) * | 2017-11-14 | 2021-05-26 | Merck Sharp & Dohme Corp. | Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
| US11498904B2 (en) * | 2017-11-14 | 2022-11-15 | Merck Sharp & Dohme Llc | Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104530029B (en) | 2017-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6186434B2 (en) | Nitrogen heterocyclic derivatives and their applications in medicine | |
| AU2019264253B2 (en) | Factor XIIa inhibitors | |
| CN102482231B (en) | Sulfonic amide and sulfoximine-substituted diaryl-dihydropyrimidinones and usage thereof | |
| CN106008488B (en) | Cyanoindole analog derivative and its preparation method and application | |
| CN104418842A (en) | Substituted indole compound and using method and application thereof | |
| CN105384739A (en) | Pyrazolo[3,4-c]pyridine derivative | |
| CN102827039B (en) | Herba Houttuyniae derivative and its application in drugs | |
| CN104530029A (en) | Heterocyclic compounds as factor Xa inhibitors as well as using methods and application of heterocyclic compounds | |
| CN104530127A (en) | Iariin derivative as well as use method and use thereof | |
| CN104311537A (en) | Pyrazolo compound containing pyrimidone acetyl substituent and composition and application thereof | |
| CN104497008A (en) | Substituted oxazolidinone compound and use method and use thereof | |
| CN104277040B (en) | Containing acyl piperazine ketone substituent pyrazolo piperidone compounds and composition thereof and purposes | |
| CN104530028A (en) | Substituted oxazolidinone compounds as well as using methods and application of substituted oxazolidinone compounds | |
| CN104496978A (en) | Substituted oxazolidinone compound and use method and use thereof | |
| CN104530046A (en) | Diazaspiro compounds and application thereof in drugs | |
| CN104311556B (en) | Pyrazoles containing epoxy alkyl substituting group piperidone compounds and composition thereof and purposes | |
| JPH0377887A (en) | Oxazopyridine derivative, its manufacture and drug compound containing said derivative | |
| CN104277037B (en) | Containing whorled pyrazolo piperidone compounds and composition thereof and purposes | |
| CN103936635A (en) | Houttuynia cordata derivatives and applications thereof in drug | |
| CN104447390B (en) | Substituted ring butanes neuraminidase inhibitor and using method thereof and purposes | |
| CN104496839B (en) | Substituted ring butanes neuraminidase inhibitor and using method thereof and purposes | |
| JP2004137185A (en) | Antimicrobial agent containing thiophene skeleton | |
| CN104530031A (en) | Oxazolidinone compounds and application thereof in drugs | |
| CN104277039B (en) | Contain the pyrazoles piperidone compounds and composition thereof and purposes that replace butynyl | |
| CN104447747B (en) | Substituted purin class neuraminidase inhibitor and using method thereof and purposes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province Patentee after: Guangdong Dongyangguang Pharmaceutical Co.,Ltd. Address before: 523808 No. 1 Industrial North Road, Songshan Industrial Park, Songshan, Guangdong, Dongguan, Hubei Patentee before: SUNSHINE LAKE PHARMA Co.,Ltd. |
|
| CP03 | Change of name, title or address |